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Abstract 1H NMR spectroscopy was used to investigate
the metabolic consequences of general anesthesia in the
plasma of two groups of patients with diagnosis for non-
metastatic colorectal cancer and metastatic colorectal
cancer with liver-metastasis, respectively. Patients were
treated with etomidate or propofol, two frequently used
sedation agents. Plasma samples were obtained via Ficoll
separation. Here, we demonstrated that this procedure
introduces a number of limitations for NMR-based meta-
bolomics studies, due to the appearance of spurious signals.
Nevertheless, the comparison of the 1H NMR metabolomic
profiles of patients treated with etomidate or propofol at
equipotent dose ranges was still feasible and proved that
both agents significantly decrease the plasma levels of
several NMR-detectable metabolites. Consequently, sam-
ples collected during anesthesia are not suitable for meta-
bolic profiling studies aimed at patient stratification,
because interpersonal variability are reduced by the overall
depression of metabolites levels. On the other hand, this
study showed that plasma metabolomics could represent a
valuable tool to monitor the effect of different sedation
agents and/or the individual metabolic response to anes-
thesia, providing hints for an appropriate tuning of per-
sonalized sedation procedures. In our reference groups, the
metabolomic signatures were slightly different in patients
anesthetized with etomidate versus propofol. The impor-
tance of standardized collection procedures and availability
of exhaustive metadata of the experimental design for the
accurate evaluation of the significance of the observed
changes in metabolites levels are critically discussed.
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Abbreviations
CA Cano nical analysis
CPMG Carr-purcell-meiboom-gill
CRC Colorectal cancer
FDR False discovery rate
GABAa C-Aminobutyric acid type A
LC Liver metastasis of colorectal cancer
MPLS Multilevel PLS
MS Mass spectrometry
NMR Nuclear magnetic resonance
NOESY Nuclear overhauser effect spectroscopy
PCA Principal component analysis
PLS Partial least squares
1 Introduction
The development of personalized medicine (determining
an individual’s disease risk, prognosis, and therapeutic
options) is fostered by high-throughput analysis of
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molecular biomarkers (DNA, RNA, protein or metabolites)
in human biospecimens (Zatloukal and Hainaut 2010;
Eckhart et al. 2012). Insufficient quality of such specimens
may lead to spurious results and data misinterpretation
(Vaught and Lockhart 2012). This is true for tissues as well
as for body fluids and the quality of these samples for
further molecular analysis depends on the pre-analytical
conditions in which they were acquired (Bernini et al.
2011; Cacciatore et al. 2013; David et al. 2014; Emwas
et al. 2014; Juhl 2010). Furthermore, the lifestyle, and more
important medication administered to a patient influence
the molecular signatures in corresponding biological
samples.
The human metabolome is composed by an ensemble of
several thousands of small molecules (\1500–2000 Da)
produced by the genome of the host organism and by the
genomes of its microflora, or deriving from food, drinks,
drugs or pollutants (Wishart et al. 2013), present on a very
ample range of concentrations (from\1 nM to[1 lM).
Blood plasma is a primary carrier of small molecules in the
body. In terms of chemical composition, the blood plasma/
serum metabolome is composed by hydrophobic (glyc-
erides, phospholipids, fatty acids, steroids, fats, steroids)
and hydrophilic (e.g. amino acids, glucose, glycerol, lac-
tate, creatinine) molecules (Psychogios et al. 2011) whose
relative concentrations reflect tissue lesions and organ
dysfunctions. As a consequence, metabolomics of serum
and plasma is increasingly used for successful patient
stratification in various diseases including colorectal cancer
(CRC), where both biofluids have shown to possess a
strong signature of the disease that allows discrimination of
CRC patients from healthy individuals and, in serum,
permitted prediction of the overall survival within a set of
metastatic patients (Bertini et al. 2012; Ma et al. 2012;
Turano 2014; Zhang et al. 2014). The NMR detectable part
of the serum/plasma metabolome generally consists of
about 50 main compounds (Psychogios et al. 2011) and
changes in the relative concentration of the molecules are
at the bases of the metabolomic fingerprinting of various
diseases. Effectively, the entire NMR spectral pattern
becomes the relevant ‘‘biomarker’’ rather than a single or a
few particular molecules.
The accuracy of metabolic profiles for clinical applica-
tions requires that the chemical composition (both in terms
of nature and levels of detectable molecules) represents as
much as possible the metabolome of the original sample,
and therefore it is little affected by pre-analytical proce-
dures. This aspect has received particular attention in
recent years and it has led to the development of validated
protocols for the collection/handling/storage of samples
dedicated to future metabolomic applications (Bernini et al.
2011; Pinto et al. 2014; Vuckovic 2012; Yang et al. 2013).
In particular, the factors influencing the stability of
metabolites during the various steps of the pre-analytical
phase for plasma and serum have been identified, leading
to the development of ad hoc standard operating proce-
dures concerning samples for metabolomics studies (Ber-
nini et al. 2011). These procedures are beginning to be
implemented in some biobanks. On the other hand, the
possibility to use one sample for multiple in vitro approa-
ches may offer advantages in studies aimed at combining
different molecular profiles (genomics, transcriptomic,
proteomics, and metabolomics).
Here, we have explored for the first time the possibility
to extract a disease signature from NMR spectra of plasma
obtained using Ficoll as separation medium and collected
from patients with non-metastatic colorectal cancer (CRC)
and metastatic colorectal cancer with liver-metastasis (LC)
patients. Additionally, we have evaluated the impact of
anesthesia on the metabolomic signature of the disease.
This work contributes to the definition of some best prac-
tice pre-analytical procedures related to sample collection
in NMR-based metabolomics studies. The observed chan-
ges that are specific for the different anesthetics within the
same group of patients, on a long-term perspective may
pave the way to the use of blood metabolomics for the
development of personalized sedation procedures.
2 Materials and methods
2.1 Patients recruitment
This study was conducted in accordance with the ethical
principles of Good Clinical Practice and the Declaration of
Helsinki. The local Ethics Committee approved the pro-
tocol before commencement of the study, and all subjects
gave written informed consent.
Seventy tumor patients, 32 female and 38 male, over
18 years of age, 40 with confirmed colorectal cancer and
30 with confirmed liver metastasis from colorectal cancer,
were recruited for this study, as summarized in Table 1. All
the participating subjects were able to understand the study
design.
Included subjects with CRC had a tumor mass greater
than 3 cm confirmed by colonoscopy and histology. Sub-
jects with LC had liver metastasis greater than 3 cm con-
firmed by an imaging method (e.g. CT). For all the patients
either hemihepatectomy or surgical tumor resection of
rectal or sigmoid tumors were scheduled. Female patients
of childbearing potential had to have a negative urine or
serum pregnancy test.
Exclusion criteria used in the selection of the subjects
included patients incapable of providing informed consent,
patients treated with a neo-adjuvant treatment (chemother-
apy or radiation) within the preceding 3 weeks, pregnant or
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lactating women, patients participating in another study of
investigational drugs or devices parallel to, or less than
1 month before study entry, or previous participation in this
study. In addition were excluded from the study employees
or family members of the investigators.
2.2 Blood collection and preparation
For each subject, blood was collected twice, the first time
prior to the administration of the anesthesia and the second
time when the patient was fully anesthetized, but before the
surgery. All blood samples were drawn from the central
infusion line and the blood was collected into commer-
cially available EDTA-treated vials.
All vials were bandaged with an absorbent cloth, stored
in a polythene bag and then immediately transferred at
4 C. Plasma samples were obtained according to Indi-
vumed standard operating procedures: EDTA-plasma was
separated from the entire blood by a density gradient
centrifugation using the Ficoll-Paque and a Leucosep Tube
allowing also the separation of the mononuclear cells
lymphocytes used for other aims. Plasma samples were
stored at -80 C until analysis.
2.3 NMR sample preparation
Frozen plasma samples were thawed at room temperature
and shaken before use. According to standard procedures
(Bernini et al. 2011), a total of 300 lL of a phosphate
sodium buffer (70 mM Na2HPO4; 20 % (v/v)
2H2O;
0.025 % (v/v) NaN3; 0.8 % (w/v) sodium trimethylsilyl
[2,2,3,3-2H4]propionate (TSP) pH 7.4) was added to
300 lL of each plasma sample, and the mixture was
homogenized by vortexing for 30 s. A total of 450 lL of
this mixture was transferred into a 4.25 mm NMR tube
(Bruker BioSpin srl) for analysis.
2.4 NMR spectra acquisition
Monodimensional 1H NMR spectra for all samples were
acquired using a Bruker 600 MHz metabolic profiler
(Bruker BioSpin) operating at 600.13 MHz proton Larmor
frequency and equipped with a 5 mm CPTCI 1H-13C-31P
and 2H-decoupling cryoprobe including a z axis gradient
coil, an automatic tuning-matching and an automatic
sample changer. A BTO 2000 thermocouple served for
temperature stabilization at the level of approximately
0.1 K at the sample. Before measurement, samples were
kept for at least 3 min inside the NMR probe head, for
temperature equilibration (300 K).
According to common practices (Beckonert et al. 2007;
Gebregiworgis and Powers 2012; Padeletti et al. 2014;
Pinto et al. 2015), for each sample, three monodimensional
1H NMR spectra were acquired with water peak suppres-
sion and different pulse sequences that allow the selective
observation of different molecular components:
(i) a standard NOESY (Nuclear Overhauser Effect
Spectroscopy) (Mckay 2011) 1Dpresat (noesygppr1d.comp;
Bruker BioSpin) pulse sequence, using 64 scans, 98,304
Table 1 Main demographic and clinical features of the patients’
cohort
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data points, a spectral width of 18,028 Hz, an acquisition
time of 2.7 s, a relaxation delay of 4 s and a mixing time of
0.1 s. This pulse sequence is designed to obtain a spectrum
in which both signals of metabolites and high molecular
weight molecules (lipids and lipoproteins) are visible.
(ii) a standard Carr-Purcell-Meiboom-Gill (CPMG)
(Carr & Purcell 1954) (cpmgpr1d.comp; Bruker BioSpin)
pulse sequence, using 64 scans, 73,728 data points, a
spectral width of 12,019 Hz and a relaxation delay of 4 s.
This pulse sequence is designed for the selective observa-
tion of small molecule components in solutions containing
macromolecules.
(iii) a standard DIFFUSION-EDITED (Tang et al. 2004)
(ledbgppr2s1d.comp; Bruker BioSpin) pulse sequence,
using 64 scans, 98,304 data points, a spectral width of
18,028 Hz and a relaxation delay of 4 s. This pulse
sequence is designed for the selective observation of
macromolecule components in solutions containing small
molecules; the resulting spectrum is generally made up
only with the lipid, lipoprotein and protein signals.
Although the CPMG spin-echo was not sufficient to
filter out the signals of the Ficoll polymeric components,
the CPMG spectra resulted more informative than the other
two types of spectra, providing the highest discrimination
accuracies in the various multivariate comparisons per-
formed. This finding indicates that the main differences
among the analyzed groups arise from the small molecules
profiles rather than from the macromolecular components.
2.5 NMR spectra processing
Free induction decays were multiplied by an exponential
function equivalent to a 1.0 Hz line-broadening factor
before applying Fourier transform. Transformed spectra
were automatically corrected for phase and baseline dis-
tortions and calibrated (glucose doublet at 5.24 ppm)
using TopSpin 2.1 (Bruker Biospin srl). Each spectrum in
the range between 0.20 and 10.00 ppm was segmented
into 0.02-ppm chemical shift bins, and the corresponding
spectral areas were integrated using the AMIX software
(Bruker BioSpin). Regions between 6.00 and 3.30 ppm
containing residual water signal and the broad and intense
absorption attributable to the Ficoll contamination (Fig. 1
and Supplementary Figure S1) were excluded in subse-
quent statistical analyses. The total spectral area was
calculated on the remaining bins and total area normal-
ization was carried out on the data prior to pattern
recognition.
2.6 Statistical analysis
Various kinds of multivariate and univariate statistical
techniques were applied on the obtained buckets using R
3.0.2 in house scripts. Principal component analysis (PCA)
was used to obtain a preliminary outlook of the data (vi-
sualization in a reduced space, clusters detection, screening
for outliers), partial least squares (PLS) and multilevel PLS
(MPLS) were employed to perform supervised data
reduction and classification. Canonical analysis (CA) was
used in combination with PLS to increase the supervised
separation of the analyzed groups. Accuracy, specificity
and sensitivity were estimated according to standard defi-
nitions. The global accuracy for classification was assessed
by means of a Monte carlo cross-validation scheme.
Twenty metabolites (plus the antibiotic Cefuroxime)
(Supplementary Table S2), whose peaks in the spectra were
well defined and resolved, were assigned. Signal identifi-
cation was performed using a library of NMR spectra of
pure organic compounds, public databases (such as
HMBD, human metabolic database, and SDBS, spectra
database for organic compounds) storing reference NMR
spectra of metabolites, spiking NMR experiments and lit-
erature data (Psychogios et al. 2011). The relative con-
centrations of the various metabolites in the different
spectra were calculated by integrating the signal area
(Wishart 2008). The Wilcoxon test was used for the
determination of the meaningful metabolites. False dis-
covery rate correction was applied using the Benjamini &
Hochberg method (FDR) (Benjamini and Hochberg 2000):
an adjusted p value of 0.05 was considered statistically
significant. The changes in metabolites levels between two
groups of spectra are calculated as the log2 fold change
(FC) ratio of the normalized median intensities of the
corresponding signals in the spectra of the two groups
(Fold change). When two groups were constituted by
individuals that could be compared in pairs (e.g. the same
individual before and after anesthesia) a pairwise analysis
was performed. Pairwise Wilcoxon test (univariate statis-
tics) and multilevel PLS (van Velzen et al. 2008; Wester-
huis et al. 2010) were used to this purpose.
2.7 Data deposition
The NMR data are available from the MetaboLights data-
base (www.ebi.ac.uk/metabolights) with the accession
number MTBLS172.
3 Results and discussion
3.1 1H NMR profiling of plasma separated by Ficoll
All the 1H NMR spectra of plasma separated by Ficoll were
different from standard plasma spectra due to the presence
of a broad and intense absorption from 3.30 to 4.64 ppm
(Fig. 1 and Supplementary Figure S1). This absorption,
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together with sharper signals at 1.81, 1.84, 2.26, 5.42 and
5.58 ppm (Supplementary Figures S2 and S3), was attrib-
uted to contamination by the Ficoll used for plasma sepa-
ration, as demonstrated by comparison with the 1H NMR
CPMG spectrum acquired on a pure Ficoll solution
(Fig. 1). Ficoll is a high molecular mass (400 kDa)
hydrophilic branched polymer formed by copolymerization
of sucrose with epichlorohydrin. CPMG pulse sequences,
which are designed for the selective observation of small
molecule components in solutions containing macro-
molecules, were not effective in removing the signals of
Ficoll, most probably due to internal dynamics of the
polymer that does not allow magnetization selection based
on relaxation times. The Ficoll spectrum contains several
signals that appear with different relative intensities in
contaminated plasma spectra. This made essentially
impossible a reliable subtraction of the Ficoll spectrum
from those of plasma samples. The presence of this con-
taminant and in particular of the broad and intense envel-
oped centered at 3.80 ppm largely limited the applicability
of standard procedures for spectral analysis, which are
based on the comparison of spectra with comparable
baselines. The analysis of the metabolomic profiles was
therefore performed by systematically excluding the cen-
tral part of the spectra (between 3.33 and 6.00 ppm, which
includes the water signal). The use of a restricted active
spectral area severely limited the number of molecules that
might contribute to the spectral signature because the
excluded spectral range contains signals form a large
number of metabolites (including glucose, proline, serine,
and threonine).
3.2 Pre-anesthesia fingerprinting of CRC versus LC
The comparison between the 1H NMR profiles CRC and
LC plasma samples is potentially relevant for the definition
of the metabolomic signature of the disease progression. A
defined metabolomic signature of CRC has been detected
in a number of studies based on the metabolic finger-
printing of plasma or serum samples of CRC patients with
respect to those of healthy controls, reaching discrimina-
tion accuracies up to 93.5 % (Ma et al. 2012). This figure
rose up to 100 % when comparing healthy subjects and
metastatic patients (Bertini et al. 2012). Here samples
collected before anesthesia were analyzed to avoid the
confounding effects deriving from the use of different
Fig. 1 a Downfield (1.00–4.00 ppm) and b upfield (5.50–8.50 ppm)
region of the 1H NMR CPMG spectra of plasma. The figure
underlines the difference between a ‘‘normal’’ plasma spectrum (red
trace) and the spectra of Ficoll-plasma samples of CRC patients
(green, blue and black traces). The baseline is heavily distorted in the
range 3.30–4.64 ppm and 5.20–5.65 ppm due to the presence of broad
unresolved features. Comparison of c. downfield (1.00–4.00 ppm) and
d. upfield (5.50–8.50 ppm) region of the 1H NMR CPMG spectra of
the Ficoll-plasma samples of CRC patients (blue, green and red
traces) and of Ficoll solution (black trace) (Color figure online)
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sedation procedures. The samples were divided into two
groups: the first contained all the pre-anesthesia of CRC
patients; the second group contained all the pre-anesthesia
samples belonging to LC patients. The discrimination
between LC and CRC obtained from the comparison of the
spectral active area of the corresponding plasma samples
was relatively weak (Fig. 2a and Supplementary Fig-
ure S4), with discrimination accuracies ranging from 74 to
76 %, depending on the type of 1H NMR spectrum
(NOESY = 74.84 %, CPMG = 76.46 %, Diffusion-edi-
ted = 73.80 %) employed for the analyses (Fig. 2b). The
value of discrimination accuracy represents the pre-
dictability of the model, i.e. the percentage of correct
classification testing the model with an unknown sample. A
percentage value of 76 % is quite low to allow the use of
this model in clinic analysis. Certainly this low value
depend on the restricted spectral areas used due to Ficoll
contamination, excluding from the analysis some metabo-
lite peaks that might contributed to the spectral signature of
CRC and LC samples.
Still, statistically significant differences in the concen-
tration of some metabolites were identified, as summarized
in Fig. 3. Most of these metabolites had been previously
identified as characteristic (up- or down-regulated in ser-
um/plasma of CRC and metastatic CRC patients with
respect to healthy subjects (Bertini et al. 2012; Ikeda et al.
2012; Leichtle et al. 2012; Ma et al. 2009; Miyagi et al.
2011; Nishiumi et al. 2012; Tan et al. 2013).
3.3 Post-anesthesia fingerprinting of CRC
versus LC
The discrimination between CRC and LC patients collected
after anesthesia was performed by dividing the spectra into
two groups: the first contained all post-anesthesia plasma
samples from CRC patients; the second group contained all
post-anesthesia plasma samples from LC. The discrimina-
tion accuracy between the two groups ranged from 85 to
Fig. 2 a Score plot of PLS-CA
discrimination of CRC and LC
patients using pre-anesthesia
samples. Red dots samples from
CRC patients. Green dots
samples from LC patients. The
plot has been constructed using
1H NMR CPMG spectra.
b Cross validation test and
confusion matrix for CRC and
LC in pre-anesthesia samples; *
sensitivity of the test; **
specificity of the test. c Score
plot of PLS-CA discrimination
of CRC and LC patients using
post-anesthesia samples. Red
dots samples from CRC
patients. Green dots samples
from LC patients. The plot has
been constructed using 1H NMR
CPMG spectra. d Cross
validation test and confusion
matrix for CRC and LC in post-
anesthesia samples; * sensitivity
of the test; ** specificity of the
test (Color figure online)
Fig. 3 Metabolites whose concentrations are significantly different
(p value\ 0.05) in pre-anesthesia plasma samples from CRC patients
compared to LC patients. The values of -Log2 (FC) and the p values
are provided. Metabolites with -Log2 (FC) negative values have
significantly higher concentration in plasma samples from CRC
patients with respect to LC patients. Metabolites with -Log2 (FC)
positive values have lower concentration in plasma samples from
CRC patients with respect to LC patients
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90 % based on the type of spectrum (NOESY = 90.35 %,
CPMG = 90.41 %, Diffusion-edited = 85.48 %) that we
considered (Fig. 2c, d and Supplementary Figure S5).
These data indicate that after anesthesia the two groups are
well discriminated from each other. The increased dis-
crimination, however, is attributable to the different phar-
maceutical treatments administered to patients with
colorectal cancer with respect to those with liver metasta-
sis, rather than to the metabolomic signature of the disease.
In general, the sedation procedures included treatment with
different anesthetics (etomidate, propofol 1 %, propofol
2 %), contemporary administration of different antibiotics
(cefuroxime, metronidazol), physiological solutions of
different saline composition (ringer, ringer acetate, ringer
lactate) and other drugs, as summarized in Supplementary
Table S1.
The definition of best pre-analytical practices for accu-
rate results of metabolomics analysis is an active field of
research (Bernini et al. 2011; Fernandez-Peralbo and
Luque de Castro 2012; Fliniaux et al. 2011; Pinto et al.
2014; Vuckovic 2012; Yang et al. 2013) and the impact of
common clinical procedures and medical intervention have
started to be considered (Cacciatore et al. 2013). The pre-
sent results clearly indicated that the NMR metabolic
profiles of samples collected immediately after drug
administration contained a strong signature of the phar-
maceutical treatment that might obscure the disease sig-
nature. Only a careful annotation of the administered
molecules allows interpreting the changes occurring in the
metabolome composition and permits spectral assignment.
3.4 Effects of anesthesia on the metabolomic profiles
The evaluation of the overall metabolic effect of the
anesthesia on all plasma samples was performed using all
sample divided into two groups: the first contained all the
samples collected before anesthesia, independently on the
cancer type; the second group contained all the samples
collected after anesthesia. In this case, the MPLS approach
was used to characterize the within-subject changes intro-
duced in the individual metabolic profile by anesthesia.
With this approach, the between-subject variations are
removed and only the within-subject treatment-related
variations are considered. The two groups are well dis-
criminated (Fig. 4a and Supplementary Figure S6). The
discrimination accuracy ranged from 90 to 93 % (Fig. 4b),
depending on the type of spectrum (NOESY = 92.43 %,
CPMG = 92.57 %, Diffusion-edited = 90.43 %). Some
peaks, which turned out to be the major discriminants in
the analyzed spectra areas, have been assigned to drugs
administered to patients. This is the case of the antibiotic
Cefuroxime, whose characteristic peaks are detectable only
in spectra of patients treated with this molecule.
Additionally, the concentration of the metabolites whose
peaks are assigned to well-known low molecular weight
components of plasma have been evaluated to determine
changes in their concentration after the anesthesia. The
analysis was performed in the CPMG spectra. The Fig. 4c
lists the metabolites whose concentration is significantly
(p value\ 0.05) decreased or increased in post-anesthesia
plasma samples. A general decrease in metabolites con-
centration was observed and it can be reasonably attributed
to a slower metabolism under anesthesia. The increased
Fig. 4 a Score plot of Multilevel PLS discrimination of pre- and
post-anesthesia CRC and LC samples. Red dots pre-anesthesia
samples from CRC and LC patients. Green dots post-anesthesia
samples from CRC and LC patients. The plot has been constructed
using 1H NMR CPMG spectra. In this type of informed analysis
samples from the same donor are compared pairwise. b Cross
validation pairwise test and confusion matrix for pre-anesthesia CRC
and LC samples (PRE) and post-anesthesia CRC and LC samples
(POST); * sensitivity of the test; ** specificity of the test. Metabolites
whose concentration is significantly different (p value\ 0.05) in pre-
anesthesia plasma samples from CRC and LC patients with respect to
post-anesthesia samples. The values of -Log2 (FC) and the p-values
are provided. Metabolites with -Log2(FC) negative values have
significantly lower concentration in post-anesthesia plasma samples
from CRC and LC patients with respect to the pre-anesthesia samples.
Metabolites with -Log2 (FC) positive values have higher concentra-
tion in post-anesthesia plasma samples from CRC and LC patients
with respect to the pre-anesthesia samples (Color figure online)
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levels of a few molecules are more difficult to interpret but
they might be directly related to the effect of some of the
medical treatments, for example acetate concentration
could increase because of the administration of Ringer
Acetate solution (Supplementary Table S1).
We further analyzed the overall effect of anesthesia on
the metabolic profiles focusing on a homogeneous set of
patients, namely the CRC patients. Within this group, two
different types of sedations were used: Etomidate and
Propofol 2 %. Samples were divided into two groups: the
first contained the samples collected after anesthesia
belonging to CRC patients treated with Etomidate; the
second group contained the samples collected after anes-
thesia belonging to CRC patients treated with Propofol
2 %. The discrimination accuracy was relatively high, of
the order of 86 % (Fig. 5a, b and Supplementary
Figure S7). The main molecular markers for the observed
differences were branched amino acids such as isoleucine
(-Log2 (FC) = 0.234), leucine (-Log2 (FC) = 0.349) and
valine (-Log2 (FC) = 0.06). Their levels were less
reduced under Propofol 2 % than under Etomidate seda-
tion, although the measured changes are not statistically
significant.
4 Concluding remarks
An incredible amount of human biosamples currently
stored in biobanks have been collected and processed by
methods that did not anticipate the demands of metabo-
lomic technologies; these samples represent a precious
resource for metabolomics research, especially when
focused on retrospective studies. Here we evaluated the
reliability of NMR-based metabolomics data on plasma
obtained from well-established lymphocyte separation via
Ficoll in 2010, when metabolomics was not part of the
design study. Although, this lymphocyte separation media
is widely used and commonly applied to blood samples, we
have shown that this procedure for plasma separation
severely limits the NMR spectral range amenable for
metabolomics analysis, excluding a number of molecules
that contribute significantly to the NMR profile. Still, the
active spectral area allowed us to measure meaningful
differences between different groups of patients and it
permitted the evaluation of the effect of anesthesia.
The changes occurring in the individual metabolome at
the systemic levels during general anesthesia were moni-
tored and some common trends observed, thus contributing
another piece to the puzzle of the possible effects on the
metabolome induced by medical intervention. From a
methodological point of view, anesthesia introduces two
confounding effects: (i) the signals of several molecules
administered to the patients at the moment of the anes-
thesia are visible in the spectra, complicating the analysis
of the NMR profiles; (ii) the levels of most plasma
metabolites are decreased at variable degrees, thus altering
the absolute and relative concentrations of metabolites
between different groups of patients and reducing the dis-
crimination capability of the method. Consequently, post
anesthesia samples are not very suitable for standard
metabolomics studies. Therefore, metabolomics studies
aiming at the stratification of patients should be carefully
conducted and patient follow-up data on medication is
essential for the interpretation of metabolomic analyses.
The comparison of pre- and post-anesthesia plasma
profiles, however, could provide hints at the molecular
level of the consequences of general anesthesia. Prior work
has shown in vivo cerebral metabolomic spectral patterns
that are anesthetic-dependent (Jacob et al. 2012; Makaryus
Fig. 5 a Score plot of PLS-CA discrimination of post-anesthesia
CRC samples from patients treated with different anesthetics. Cyan
dots samples from CRC patients treated with etomidate. Magenta dots
samples from CRC patients treated with propofol 2 %. The plot has
been constructed using 1H NMR CPMG spectra. b Cross validation
pairwise test and confusion matrix for plasma samples from CRC
patients treated with different anesthetics;* sensitivity of the test;
** specificity of the test
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et al. 2011). Here we demonstrated that Propofol 2 % and
Etomidate, which are known to act by selectively potenti-
ating GABAa (c-aminobutyric acid type A) receptors to
provide very similar sedation, but to have some different
side effects (Hemmings et al. 2005; Miner et al. 2007; Yip
et al. 2013), induce small but meaningful differences in the
plasma metabolic profiles at the systemic level. This
molecular information is readily accessible via NMR pro-
filing and may complement classical clinical signs for the
evaluation of sedation agents and procedures.
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